Wm164

Manufactured by American Type Culture Collection

Sourced in United States

The WM164 is a laboratory equipment product designed for culturing cells. It provides a controlled environment for cell growth and maintenance. The WM164 regulates temperature, humidity, and gas composition to support optimal cell culture conditions.

Automatically generated - may contain errors

Lab products found in correlation

Hek293, by American Type Culture Collection (3 mentions) Wm983a, by Rockland Immunochemicals (2 mentions) Wm983b, by Rockland Immunochemicals (2 mentions) Colo829 cells, by American Type Culture Collection (2 mentions) Dulbecco modified eagle medium (dmem), by Thermo Fisher Scientific (2 mentions) Chl 1, by American Type Culture Collection (2 mentions) Hsc 3, by Japanese Collection of Research Bioresources Cell Bank (1 mentions) Penicillin streptomycin, by Thermo Fisher Scientific (1 mentions) Mycoalert mycoplasma detection kit, by Lonza (1 mentions) Sk mel 28, by American Type Culture Collection (1 mentions) Uacc903, by American Type Culture Collection (1 mentions) Wm 239, by American Type Culture Collection (1 mentions)

5 protocols using wm164

Cell Line Maintenance and Validation

Check if the same lab product or an alternative is used in the 5 most similar protocols

HEK293, A375, WM164 cell lines were purchased from ATCC. WM983A and WM983B cell lines were purchased from Rockland (Philadelphia, PA). Melanocytes (CDKN2A null) were provided by Dr. Ian Robert Watson (McGill University). All cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (GIBCO) with 4.5 g/liter glucose supplemented with 10% fetal bovine serum (FBS), 100 IU/ml penicillin, and 100 µg/ml streptomycin, under 37 °C/5%CO₂ conditions. Colo829 cells were purchased from ATCC and maintained in Roswell Park Memorial Institute Medium (RPMI) with 10% FBS, 100 IU/ml penicillin and 100 µg/ml streptomycin, under 37 °C/5%CO₂ conditions. Cells were regularly tested by PCR to exclude mycoplasma contamination.

Houles T., Lavoie G., Nourreddine S., Cheung W., Vaillancourt-Jean É., Guérin C.M., Bouttier M., Grondin B., Lin S., Saba-El-Leil M.K., Angers S., Meloche S, & Roux P.P. (2022). CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma. Nature Communications, 13, 6457.

+ Open protocol

+ Expand

Culturing Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human tongue squamous cell carcinoma cell line, HSC-3, was obtained from JCRB Cell Bank and authenticated by isoenzymology. The human melanoma cell line, WM164, was purchased from ATCC and authenticated by short tandem repeat profiling. Cells were cultivated in Dulbecco's Modification of Eagle's Medium (DMEM) with 4.5 g/L glucose, L-glutamine and sodium pyruvate, 10% fetal bovine serum (FBS), at 37 °C in 5% CO₂.

Viet C.T., Dang D., Ye Y., Ono K., Campbell R.R, & Schmidt B.L. (2014). Demethylating Drugs as Novel Analgesics for Cancer Pain. Clinical cancer research : an official journal of the American Association for Cancer Research, 20(18), 4882-4893.

+ Open protocol

+ Expand

Cell Line Maintenance and Authentication

Check if the same lab product or an alternative is used in the 5 most similar protocols

HEK293, A375, WM164 cell lines were purchased from ATCC. WM983A and WM983B cell lines were purchased from Rockland (Philadelphia, PA). All cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (GIBCO) with 4.5 g/liter glucose supplemented with 10% fetal bovine serum (FBS), 100 IU/mL penicillin, and 100 µg/mL streptomycin, under 37 °C/5%CO₂ conditions. Colo829 cells were purchased from ATCC and maintained in Roswell Park Memorial Institute Medium (RPMI) with 10% FBS, 100 IU/mL penicillin and 100 µg/mL streptomycin, under 37 °C/5%CO₂ conditions. Cells were regularly tested by PCR to exclude mycoplasma contamination.

Houles T., Boucher J., Lavoie G., MacLeod G., Lin S., Angers S, & Roux P.P. (2023). The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma. Cell Death Discovery, 9, 459.

+ Open protocol

+ Expand

Cell Line Maintenance and Mycoplasma Testing

Check if the same lab product or an alternative is used in the 5 most similar protocols

The commercially available cell lines CHL-1 (human melanoma), HEK-293 (human embryonic kidney), PC-3 (human prostate carcinoma), and WM-164 (human melanoma) were obtained from American Type Culture Collection (Manassas, VA, USA). All the cell lines were maintained in DMEM supplemented with 10% fetal bovine serum 5 mM ultraglutamine and 100 U/ml penicillin–streptomycin (Gibco; Carlsbad, CA, USA). ). The cells were regularly tested for mycoplasma contamination using MycoAlert® Mycoplasma Detection Kit (Lonza; Basel, Switzerland).

Kaprio H., Siddiqui A., Saustila L., Heuser V.D, & Gardberg M. (2023). The oncogenic properties of the EWSR1::CREM fusion gene are associated with polyamine metabolism. Scientific Reports, 13, 4884.

+ Open protocol

+ Expand

Melanoma Cell Lines and Vemurafenib Resistance

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human melanoma cell lines (A375, SK-mel-28, UACC903, MGH-MC-1, K4, WM239, WM1158, WM164, G-mel, CHL-1, SK-mel-119) were developed in-house, purchased from the American Type Culture Collection (Rockville, MD) or gifts from Meenhard Herlyn (Wistar Institute, Philadelphia, PA). Vemurafenib resistant melanoma cell lines (A375-P, SK-Mel 28-P, UACC903-P, MGH-MC-1-P, K4-P, WM239-P and WM1158-P) were obtained by sequentially exposing of cells to escalating doses of VEM in 2014. DMEM medium with 10% fetal bovine serum (FBS), supplemented with 100 units/ml penicillin, 100 μg/ml streptomycin, and 2 mM glutamine was used for routine culturing of cells; VEM-resistant cells were cultured in VEM-free media for 10–14 days prior to re-testing VEM sensitivity; this drug holiday period had no effect on the VEM resistance (data not shown). All cells were incubated in a humidified atmosphere of 95% air and 5% CO₂ at 37°C. Tumor specimens from patients were obtained prior to treatment with BRAFi (vemurafenib) or BRAFi+MEKi (dabrafenib+trametinib) and post-relapse as indicated in Table S1. Acquisition of tissue was covered under a protocol approved by the DF/Harvard Cancer Center (legacy #11-181; Boston, U.S.) in accordance with the Declaration of Helsinki.

Miao B., Ji Z., Tan L., Taylor M., Zhang J., Choi H.G., Frederick D.T., Kumar R., Wargo J.A., Flaherty K.T., Gray N.S, & Tsao H. (2014). EphA2 is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma. Cancer discovery, 5(3), 274-287.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!